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Bee venom (BV), secreted from the venom gland of the honey 
bee, contains several biological active compounds. BV has 
been widely used as a traditional medicine for treating human 
disease, including cancer. In this study, we have shown the 
molecular mechanism underlying the therapeutic effect of BV 
on cancer. Treatment with BV reduced the proliferation of 
cervical-cancer cells in a dose- and time-dependent manner. 
Interestingly, the killing effect of BV was specific to HPV- 
positive cervical-cancer cell lines, such as Caski and HeLa 
cells, and not to HPV-negative cervical-cancer cells (C33A). 
BV reduced the expression of HPV E6 and E7 at RNA and 
protein levels, leading to an increase in the expression of p53 
and Rb in Caski and HeLa cells. Further, BV decreased the 
levels of cell-cycle proteins, such as cyclin A and B, and 
increased the levels of cell-cycle inhibitors, such as p21 and 
p27. BV significantly induced apoptosis and inhibited wound 
healing and migration of cervical-cancer cells. It also upregu-
lated the expression of pro-apoptotic BAX and downregulated 
the expression of anti-apoptotic Bcl-2 and Bcl-XL. Cleavage of 
caspase-3, caspase-9, and PARP were also induced by BV 
treatment, whereas the phosphorylation of mitogenic signaling- 
related proteins, such as AKT, JNK, p38, and ERK, were 
downregulated. Our results indicate that BV has a therapeutic 
selectivity for HPV-positive malignant cells, so further clinical 
studies are needed to assess its clinical application. [BMB 
Reports 2020; 53(8): 419-424]
INTRODUCTION
Cervical cancer (CC) is one of the most common malignant 
cancers in women, with an estimated global mortality rate of 
0.25 million deaths per year (1). Cervical cancer is caused by 
HPV infection, which is related to the metaplastic epithelium 
of the cervical transformation zones (2). Cervical cancer 
originates from abnormal cells in the lining of the uterine 
cervix. There are two primary types of cervical cancer, squamous- 
cell cancer and adenocarcinoma. Squamous-cell cancer is the 
most common, and accounts for more than 70 of every 100 
cases of cervical cancer. The incidence of adenocarcinoma has 
been reported to be less than that of squamous-cell cancer, but 
lately it has become more frequent (3). According to inter-
national guidelines, the standard treatment for CC consists of 
surgery in early-stage tumors, concomitant chemoradiation or 
neoadjuvant chemotherapy, followed by radical surgery in 
locally advanced disease, and chemotherapy alone for meta-
static or recurrent disease (NCCN guidelines). Although early- 
stage and locally advanced cancer can be treated with 
potential curative intent (4), the removal of the cervix and 
uterus during surgery makes it impossible for the patient to 
become pregnant. Therefore, new therapeutic targets are needed 
to prevent problems with pregnancy and to improve the 
quality of life of women undergoing treatment for CC.
A possible way to inhibit the growth of cancer cells without 
any side effects is to use oriental medicine, such as bee venom 
(BV) (5). BV is secreted from the venom gland of the honey 
bee and contains several biologically active compounds (6). 
BV therapy is commonly used in Korean medicine as a treat-
ment for various human diseases (7). Currently, BV targeted 
therapy has been developed for clinical treatment of conditions 
such as immune-related disorders. Recently several studies 
have helped explain the anti-cancer effect of BV on lung, liver, 
renal, prostate, breast and cervical-cancer cells (8). Melittin 
and phospholipase A2, known BV peptides, can serve as 
valuable, novel targets in the treatment of some types of 
cancer. However, further studies are required to investigate the 
therapeutic effect of BV on cervical cancer.
In this study, we demonstrated the therapeutic mechanism 
of BV in cervical-cancer cells, and more specifically, we 
identified the therapeutic effect of BV on HPV-positive and 
-negative cell lines. We detected induced apoptosis and reduced 
cell motility after BV treatment. Finally, we also investigated 
the expression of cell-cycle-regulated proteins and phosphoryl-
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Fig. 1. Bee venom inhibits the prolife-
ration and expression of HPV E6 and 
E7-positive cervical-cancer cells and 
increases the expression of p53 and 
Rb proteins. (A) WST cell proliferation 
assay showing dose-dependent inhibition 
of C33A, Caski and HeLa cells. C33A, 
Caski, and HeLa cells were treated with 
0, 0.625, 1.25, 2.5, 5, and 10 g/ml 
of BV for 24 h (B). At 0, 12, 24, and 
48 h of treatment, we detected cell 
proliferation by MTT assay. (C) RT-PCR- 
based detection of time-dependent 
effects of 5 g/ml of BV on the expres-
sion of HPV proteins, HPV16 E6, HPV 
16 E7, HPV18 E6, and HPV E7 in 
C33A, Caski and HeLa cells treated for 
0, 12, and 24 h. (D) Protein levels of 
HPV16 E6, HPV16 E7, p53, and Rb in 
Caski and HeLa cells treated with 0, 
1, 5, and 10 g/ml BV. -actin was 
used as a loading control. 
Fig. 2. Bee venom significantly induces 
apoptosis in HPV E6 and E7-positive 
cervical-cancer cells. (A) Representative 
data obtained from flow-cytometric 
analysis of cell-cycle markers after treat-
ment of Caski cells with 5 g/ml of 
BV for 0, 12, and 24 h. We fixed 
cells using 1% PFA and stained DNA 
with PI as described in Materials and 
Methods. (B) Caski Cells were treated 
with BV 5 g/ml for 24 h and harvest-
ed; then DNA was stained with pro-
pidium iodide before analysis using FACS.
ation of mitotic signaling-related proteins. Our results show 
that BV could serve as a potent cervical-cancer therapy agent.
RESULTS
Bee venom inhibits the proliferation and expression of HPV 
E6 and E7 and increases the expression of p53 and Rb proteins 
in HPV-positive cervical-cancer cells
To find out whether BV suppresses cell proliferation, we 
treated cervical-cancer cell lines Caski, C33A, and HeLa cells 
with various concentrations of BV (0.625–10 g/ml). We ob-
served a reduction in the proliferation rates of Caski and HeLa 
cells starting at 2.5 g/ml, although the same was not true for 
C33A cells (Fig. 1A). We then treated cells with 5 g/ml of BV 
in a time-dependent manner. We found that over time, the 
proliferation rates of Caski and HeLa cells were reduced by 
half in response to the treatment; however, C33A cells did not 
respond to BV (Fig. 1B). Next, we treated the cells with 5 g/ 
ml of BV and harvested them at various times (0, 12, and 24 
h). We showed that mRNA levels of HPV16 E6 and E7, and 
HPV18 E6 and E7 were decreased in Caski and HeLa cells 
(Fig. 1C). Since BV treatment of C33A cells did not result in 
any changes in cell proliferation, we did not quantify the 
mRNA expression of genes mentioned above. Moreover, we 
investigated the levels of their respective proteins after treating 
Caski and HeLa cells with various concentrations of BV. 
Protein expression of HPV16 E6 and HPV16 E7 was decreased 
upon increasing the concentrations of BV, whereas the expres-
sion of p53 and Rb was increased (Fig. 1D). Overall these 
results strongly suggest that BV downregulates mRNA expres-
sion of E6 and E7, which leads to an increase in p53 and Rb 
expression, and thus inhibition of cervical-cancer cell proliferation. 
Bee venom significantly induces apoptosis in HPV-positive 
cervical-cancer cells
To further investigate whether BV affects cell fate, we carried 
out PI staining analysis after treating Caski cells with BV. We 
found that, starting after 12 h treatment, the number of cells 
entering the sub-G1 phase had increased (Fig. 2A). We then 
measured the induction of apoptosis in BV-treated Caski cells 
using annexin V staining followed by FACS analysis, and 
observed an increase of annexin V positive cells in Caski cells. 
Less than 10% of BV-untreated cells exhibited background 
staining with annexin V, whereas after BV treatment, more 
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Fig. 4. Bee venom regulates the expres-
sion of cell-cycle inhibitors, apoptosis- 
related proteins, and mitogenic signaling- 
related proteins. (A) Western blot show-
ing the time-dependent effects of BV 
on Rb, cyclin A, and cyclin B in 
Caski and HeLa cells treated for 0, 12, 
and 24 h with BV (5 g/ml). (B) Expres-
sion of p53, p21, and p27 in Caski 
and HeLa cells treated with 5 g/ml 
of BV was measured at 0, 12, and 24 
h by Western blot. (C) Western blot 
of Caski and HeLa cells treated with 
5 g/ml of BV for 0, 12, and 24 h. 
Immunoblot analysis of Bax, Bcl-2, Bcl- 
XL, pro-caspase-3, pro-caspase-9, and 
cleaved PARP. (D) We measured protein 
levels of p-AKT, AKT, p-JNK, JNK, p-P38, 
P38, p-P44/42, and P44/42 by Western 
blot in Caski and HeLa cells treated 
with 5 g/ml of BV for 0, 12, and 24 
h. -actin was used as a loading con-
trol. Data are presented as mean ± SD 
(n = 3). Significant differences are 
indicated with an asterisk (*P ＜ 0.05, 
*P ＜ 0.01), P values were calculated 
using the Student’s t test. 
Fig. 3. Bee venom decreases the migration of HPV E6- and E7- 
positive cervical-cancer cells. (A) We treated Caski and HeLa cells 
with BV (5 g /ml) for 0, 12, 24, and 48 h. (B) Transwell 
migration assay. Caski and HeLa cells were treated with 5 g/ml 
of BV for 0, 12, and 24 h, and seeded into the upper chamber 
of a Transwell plate, before being allowed to vertically migrate 
towards the lower surface of the membrane. Migrating cells were 
stained with 0.1% crystal violet.
than 46% of the Caski cells were stained with annexin V, 
indicating induction of apoptosis and an increased population 
of dead cells (Fig. 2B). Overall, these data suggest that BV 
treatment induces apoptosis in HPV-positive cervical-cancer 
cells.
Bee venom decreases cell motility of HPV-positive 
cervical-cancer cells
We investigated whether BV-induced morphological changes 
could be linked to cell migration. In the background of BV 
treatment (5 g/ml) in Caski cells and HeLa cells, we did 
wound healing (Fig. 3A) and migration assays (Fig. 3B). After 
BV treatment, we investigated cell motility at various times, 
including 0, 12, 24, and 48 h. We found that BV-treated Caski 
and HeLa cells exhibited less motility than did untreated cells 
(Fig. 3A and 3B). These results suggest that BV inhibits cell 
motility in HPV-positive cervical-cancer cells.
Bee venom decreases the expression of cell-cycle-related 
proteins in HPV-positive cervical-cancer cells
We showed that BV regulates cell-cycle proteins in HPV E6 
and E7 oncogene-expressing cervical-cancer cells. Using Western 
blot analysis, we investigated the expression of cell-cycle proteins 
in BV-treated (5 g/ml) Caski and HeLa cells. BV treatment led 
to a significant increase in the protein levels of Rb and de-
creased the levels of cyclin A and cyclin B proteins (Fig. 4A).
To further investigate whether BV regulates the expression of 
tumor suppressors and cyclin-dependent kinase inhibitors, we 
checked the protein expression of p53, p21Cip1, and p27kip1 
after BV treatment at 12 and 24 h. As expected, levels of these 
proteins were increased in Caski and HeLa cells (Fig. 4B). 
Bee venom regulates the expression of apoptosis-related 
proteins
We also investigated the effect of BV on the expression of 
apoptosis-related proteins. The levels of pro-apoptotic protein 
Bax increased after BV treatment, but those of the anti-apop-
totic proteins Bcl-2 and Bcl-X decreased (Fig. 4C). Consequent-
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ly, pro-caspase-3, pro-caspase-9, and PARP were cleaved into 
their active forms (Fig. 4C). 
Bee venom downregulates the mitogenic signaling pathways
We also investigated whether mitogenic signaling pathways 
are regulated by BV. We measured the expression of proteins 
related to the AKT, JNK, and mitogen-activated protein kinases 
(P38, P44/42) signaling pathways in HPV E6- and HPV E7- 
positive cervical-cancer cells. Compared with BV-untreated 
cells, the phosphorylation of these proteins was decreased in a 
time-dependent manner in response to BV treatment (Fig. 4D).
DISCUSSION
HPV (Human Papilloma Virus) is known to be a prerequisite 
for the development of cervical cancer (9). Increased expres-
sion of E6 and E7 is responsible for the carcinogenic effects of 
HPV (10). Thus, mRNA expression of HPV E6 and E7 is 
correlated with the progression of cervical cancer. Accordingly, 
HPV E6 and E7 are used as markers for the diagnosis of 
cervical cancer (11). Given that the cervix is directly linked to 
female reproduction, it is crucial to find treatment options 
without adverse effects. However, surgery, chemotherapy, and 
radiation therapy are associated with infertility. For addressing 
this problem, research on alternative treatment approaches is 
actively under way. Biotoxin-based approaches can also serve 
as alternative treatments for cancer. One biotoxin in particular, 
bee venom, is widely known as a treatment for immune- 
related diseases. Recent studies have shown that the main 
peptide component of BV, melittin, has an anti-cancer effect 
(12, 13). Melitin is a non-specific cytolytic peptide that can 
break down lipid bilayers and is toxic when injected (14). 
However, via an optimized nanoparticle-based approach, it 
exhibits anti-cancer effects on several cancer cells, including 
leukemia, liver cancer, lung cancer, and prostate cancer cells 
(15). 
In this study, we confirmed that BV can effectively treat HPV 
E6 and E7-infected cervical-cancer cells. This could help us in 
specifically targeting cervical-cancer cells. We confirmed that 
BV downregulated the proliferation in HPV E6 and HPV 
E7-positive cervical-cancer cells; p53 and Rb, both tumor-sup-
pressive proteins, are associated with HPV E6 and E7 proteins, 
suggesting a mechanism for viral proteins to induce cervical 
cancer (16). E6 protein promotes the degradation of the tumor 
suppressor p53 by forming a trimeric complex consisting of 
E6, p53, and a cellular ubiquitin ligase, E6-AP, thereby promot-
ing the progression of cancer cells (17). A decrease in the 
levels of E6 proteins inhibits P53 function, thereby deregu-
lating the cell cycle and stimulating the growth of cancer cells 
(18). Here, we observed an increased expression of p53 and 
Rb proteins in cervical-cancer cells after treatment with BV. In 
addition, several reports have shown that BV induces caspase- 
dependent apoptosis (19). Our results revealed that the expres-
sion of Bcl2 family proteins was greatly altered, a pheno-
menon that seems to be a direct result of p53 activity.
In addition, we investigated whether BV affects mitogenic 
signaling pathways. The AKT signaling pathway plays an 
important role in various biological processes and in cancer 
progression and survival (20). Akt is activated through phos-
phorylation at the serine 473 residue (21). Activated Akt can 
phosphorylate downstream proteins, such as mTOR, BAD, and 
FOXO1, to regulate cancer-cell proliferation and viability. The 
JNK pathway is one of the pathways downstream to AKT and 
plays a crucial role in apoptosis and cancer-cell fate determi-
nation (22). Two upstream MAPKKs promote JNK activation 
(23). The MAPK signaling pathway plays a crucial role in 
tumor growth and apoptosis (24), and p38, a major MAP 
kinase is activated in cells in response to apoptosis and 
inflammatory cytokines. MAP/ERK kinase 1 and 2 phosphoryl-
ate p42 and p44 (ERK) MAP kinases. MAP3Ks trigger p28 
MAPK activation, which promotes the activation of the JNK 
pathway (25), and p38 MAPK is an important factor in determi-
ning cancer-cell fate (26). We observed a significant decrease 
in AKT, JNK, p38, and p44/42 signals following BV treatment. 
Additionally, BV also inhibited the phosphorylation of these 
proteins in HPV E6 and E7 positive cervical-cancer cells. 
Taken together, this study demonstrates that BV can play a 
role in inhibiting cervical-cancer tumorigenesis. Therefore, we 
posit that BV is an ideal approach for treating cervical cancer.
MATERIALS AND METHODS
Cell line preparation and Bee venom treatment 
We obtained human cervical-cancer cell lines, C33A, Caski, 
and HeLa, from ATCC (Manassas, VA, USA). Cell lines were 
maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% fetal bovine serum (FBS) and 1% antibiotics 
(Invitrogen, Carlsbad, CA, USA), at 37oC in 5% CO2 atmos-
phere, as previously described (27, 28). Cervical-cancer cells 
were seeded in 6-well plates and subsequently treated with BV 
0-10 g/ml for 24 h. Bee Venom (Apis mellifera caucasia), 
Dried Bee Venom Powder was purchased by MyBiosouece 
(San Diego, USA).
Analysis of cell proliferation
We seeded cervical-cancer cells, C33A, Caski, and HeLa in 
96-well culture plates (3 × 103 cells/well). After 24 h, we treated 
C33A, Caski and HeLa cells with BV (0-10 g/ml) for 24 h. 
Following this treatment, highly sensitive water-soluble tetra-
zolium salt (WST) solution, purchased from Daeil (Seoul, 
Korea), was added to each well. After 1-3 h of incubation, we 
measured absorbance using an ELISA reader at a test 
wavelength of 450 nm (29, 30).
Detection of cell cycle and apoptosis
Caski cells were seeded in culture plates and treated with 5 
g/ml of BV. Cells were harvested and then fixed with 70% 
EtOH (5 ml) overnight at −20oC. After fixation, cells were 
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resuspended in propidium iodide (PI solution; RNaseA 50 
g/ml, PI 50 g/ml in PBS) and transferred to FACS filter tubes. 
We evaluated cell-cycle distribution by PI staining using 
fluorescence-activated cell sorting (FACS). Caski cells were 
seeded in culture plates and treated with 5 g/ml of BV. After 
24 h, cells were harvested and resuspended (1 × 106 cells/ml) 
in Annexin V. Then, we transferred the solution (100 l) to a 
1-ml culture tube, and added 5 l of FITC Annexin V and 
7-AAD to each sample. Cells were incubated for 15 min at RT 
in the dark. Then, we added 400 l of 1x Annexin Binding 
Buffer to each tube, after which the solution was transferred to 
FACS filter tubes. We measured apoptosis distribution by 
Annexin V staining using FACS (31).
Wound-healing assay
Caski and HeLa cells were seeded in 12-well plates and 
treated with 5 g/ml of BV. A straight wound was created by 
scratching the cell surface with a 200-l pipette tip. Cells, 
maintained in serum-free DMEM, migrated to the wound area; 
these were then imaged using wide-field microscopy at 0, 12, 
24, and 48 h (32).
Transwell migration assay
We treated Caski and HeLa cells with 5 g/ml of BV. After 
24-h of treatment, cells (2 × 104/well) were isolated and 
added into the upper chamber of a Transwell plate (Corning, 
New York, USA). Chambers coated with 0.5 mg/ml collagen 
type I were purchased from BD bioscience (Seoul, Korea) for 
the migration assay. We added DMEM supplemented with 
10% FBS and 1% antibiotics to the lower chamber. Cells were 
then incubated for a further 24 h, and those that migrated to 
the lower chamber were quantified after H&E staining. For 
quantification, cells were counted in 5 randomly selected 
areas in each well using wide-field microscopy. Data were 
expressed as mean ± SEM from three independent experiments.
Western blot analysis
Cells were lysed in RIPA buffer (Biosesang, Seoul, Korea) 
containing an Xpert protease-inhibitor cocktail (GenDEPOT, 
Barker, TX, USA) and a phosphatase inhibitor (NaF, Na3VO4). 
The cell lysate was centrifuged at 13,200 rpm for 20 min at 
4oC, after which the supernatant was collected. Proteins (20 
g) were separated by SDS-PAGE and transferred onto PVDF 
membranes (Merck Millipore, Darmstadt, Germany). After 
transfer, membranes were blocked with 5% skim milk (Becton 
Dickinson, Sparks, MD, USA) and incubated with primary 
antibody prepared in 5% BSA (Bovagen Biologicals, Victoria, 
Australia) overnight at 4oC. We then probed membranes with 
HRP-conjugated anti-mouse or anti-rabbit secondary antibody 
(Bethyl Laboratories, Montgomery, TX, USA) for 1 h. Protein 
bands were detected by Clarity western ECL substrate (Bio-Rad, 
Hercules, CA, USA) using LAS 3000 (29). The following 
antibodies were used: anti--actin, anti-Rb, anti-Cyclin A, anti- 
Cyclin B, anti-P53, anti-P21, anti-P27, anti-BAX, anti-BCl 2, anti- 
BCl-XL, anti-P-Akt, anti-Akt, anti-p-JNK, anti-JNK, anti-p-P38 
anti-P38, anti-p-P44/42, and anti-P44/42 (Santa Cruz, Dallas, 
TX, USA). We also used anti-pro-caspase3 and anti-pro-caspase9 
antibodies that were purchased from Cell Signaling Technology 
(Beverly, MA, USA).
Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
We extracted total RNA from cells using Isol-RNA Lysis 
Reagent, which was purchased from 5prime (Gaithersburg, 
MD, USA) and used according to the manufacturer’s protocol 
(33). We synthesized cDNAs using 1 g of total RNA by using 
ReverTra Ace® qPCR RT Master Mix (TOYOBO, Tokyo, Japan). 
We did PCR using EX-taq DNA Polymerase, purchased from 
TaKaRa (Kyoto, Japan). The primer sequences were as follows: 
-actin, 5'-AGCCTCGCCTTTGCCGA-3' (sense) and 5'-CTG 
GTGCCTGGGGCG-3' (anti-sense); HPV16 E6, 5'-GAA 
CAGCAATACAACACAAACCG-3' (sense) and 5'-CCACCGAC 
CCCTTATATTATG-3' (anti-sense) HPV16 E7, 5'-CAGCTCAGA 
GGAGGAGGATG-3' (sense) and 5'-CACAACCGAAGCGTAGA 
GTC-3' (anti-sense); HPV18 E6, 5'-ATCCAACACGGCGACCC 
TACAA-3' (sense) and 5'-CTGGATTCTATGTCACGAGCAAT-3' 
(anti-sense); HPV18 E7, 5'-ACCTTCTATGTCACGAGCAAT-3' 
(sense) and 5'-CGGACACACAAAGGACAGGGT-3' (anti-sense); 
P53, 5'-GGCCCACTTCACCGTACTAA-3' (sense) and 5'-GTGG 
TTTCAAGGCCAGATGT-3' (anti-sense); and Rb, 5'-TGTATCG 
GCTAGCCTATCTC-3' (sense) and 5'-AATTAACAAGGTGTGG 
TGG-3' (anti-sense).
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